微創醫療(00853.HK)附屬擬折價售股,預計融資4.58億港元用於運營
格隆匯5月14日丨微創醫療(00853.HK)發佈公吿,2025年5月14日(交易時段之前),公司間接全資附屬公司上海默化與配售代理(摩根大通及中金公司)訂立大宗交易協議,據此,上海默化已同意透過配售代理個別但非共同或共同及個別出售最多3016.35萬股銷售股份,佔截至本公吿日期上海醫療機器人全部已發行股本的約3.00%,由配售代理按竭力基準促使按銷售價向承配人出售。銷售價為每股H股15.50港元,相等於配售價,即較最後交易日聯交所所報每股H股收市價17.98港元折讓約13.79%。
同時,上海醫療機器人(02252.HK)與配售代理訂立配售協議,據此,上海醫療機器人同意透過配售代理個別但非共同或共同及個別配售最多2513.65萬股配售股份,佔截至本公吿日期上海醫療機器人全部已發行股本的約2.50%,由配售代理按竭力基準促使按配售價向承配人配售。
假設所有銷售股份均獲成功配售,預期銷售事項所得款項淨額將約為4.58億港元,將用作一般營運資金。於銷售事項及配售事項完成後,並假設所有銷售股份及配售股份均獲成功配售,集團所擁有上海醫療機器人的已發行股本將由約48.08%攤薄至約43.98%。連同上海默化的一致行動人士上海擎禎企業管理諮詢中心(有限合夥)所持有的1.64%的股權,集團於上海醫療機器人的權益將達到45.63%。因此,於銷售事項及配售事項完成後,上海醫療機器人將仍為公司附屬公司,且其財務業績將繼續綜合計入集團財務報表。因此,銷售事項及配售事項將不會導致於集團綜合損益表確認任何收益或虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.